Background Herceptin, a humanized antibody to HER‐2, is now utilized in the clinic for
metastatic breast cancer treatment. The response rate for HER‐2+ patients is only 30% and …

Background. Herceptin is a humanized antibody that binds to the product of the HER-2
oncogene. Clinical studies have indicated that treatment with Herceptin may slow disease …

Clinical resistance to the HER-2 oncogene–targeting drug trastuzumab (Herceptin) exists,
but studies of the resistance mechanisms are hampered by the lack of suitable experimental …

HER-2 is overexpressed in 20–25% of invasive breast cancers and is associated with an
aggressive tumor phenotype and reduced survival rate. The HER-2 status of a tumor is the …

Herceptin is the first therapy for breast cancer which targets an oncogene product. This
humanized antibody to HER-2 has been shown to have activity as a single agent in a phase …

Amplification of the human epidermal growth factor receptor-2 (HER2) gene and
overexpression of the encoded protein are seen in 20-30% of breast cancers, and are …

Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody directed against
HER-2. The objective response rate to trastuzumab monotherapy is 12–34% for a median …

Abstract Her2 (erb B2/neu) is overexpressed in 25–30% of human breast cancers. Herceptin
is a recombinant humanized Her2 antibody used to treat breast cancer patients with Her2 …

Purpose: We have investigated mechanisms of acquired resistance to the HER2 antibody
trastuzumab in BT-474 human breast cancer cells. Experimental Design: BT-474 xenografts …

Overexpression of human epidermal growth factor receptor-2 (HER-2) oncoprotein is an
important prognostic factor associated with a poor prognosis in breast cancer. Although …